Company Overview
About Third Arc Bio
Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.
Business Model & Competitive Advantage
Bispecific T cell engagers (BiTEs) work by simultaneously binding a cancer-specific antigen on tumor cells and CD3 on T cells, bringing T cells into direct contact with cancer cells to trigger targeted tumor destruction. This approach has validated efficacy in hematologic cancers (blinatumomab, FDA-approved), but extending it to solid tumors requires addressing the immunosuppressive tumor microenvironment that prevents T cells from functioning effectively in solid cancer contexts. Third Arc's multifunctional antibody architecture addresses this by incorporating additional mechanisms beyond simple T cell engagement.
Competitive Landscape 2025–2026
Andreessen Horowitz's decision to enter Third Arc as a new investor in the extension round — rather than waiting for the company's Series B — reflects strong conviction in the program's Phase 1 safety and early efficacy data, and positions a16z Bio at the earliest point in Third Arc's anticipated value creation curve.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Third Arc Bio is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Third Arc Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Third Arc Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Third Arc Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Third Arc Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →